Heptares Review Article Highlights Promise of Structure-Based Drug Design for G-Protein Coupled Receptors (GPCRs)

Review published in Trends in Pharmacological Sciences

Heptares grants Shire an Exclusive Worldwide License to Develop and Commercialise Novel Drug Candidate for CNS Disorders

Heptares to Present at 6th Annual BIO-Europe Spring Conference on 20 March 2012

Leading Japanese Scientists From Pharmaceutical Companies and Academia Attend GPCR Drug Discovery Symposium Hosted By Heptares Therapeutics

Breakthroughs and Insights for Structure-Based Design of GPCR Targeted Medicines

Heptares to Present at 5th Annual European Life Science CEO Forum On 6 March 2012

Heptares’ Patents Covering Stabilised Receptor (StaR®) Technology Granted in Europe and Japan

Key patent grants protect Heptares’ leading position in GPCR-targeted drug design and discovery

Heptares Scientists Report The First Use of Structure-Based Design to Discover GPCR-Targeted Drug Candidate

Heptares Expands Executive Management Team with Appointment of Daniel Grau as President

Company to advance pipeline in neurological and metabolic areas, while harnessing broader discovery platform through alliances

Heptares Scientists Generate New Insight Into Caffeine's Molecular Pharmacology To Drive Design Of Next-Generation CNS Therapeutics

First 3-D X-ray Co-structures of Caffeine and other Xanthines Bound to G-Protein Coupled Receptor (GPCR) Published in the Journal Structure

Heptares Biophysical Mapping™ Featured in the Journal of Medicinal Chemistry

New Technology Elucidates GPCRs and Accelerates Structure-Based Design of GPCR Targeted Medicines